Synergy Pharmaceuticals Inc fka SGYPQ

[Snackman]

Synergy, meanwhile has been executing well on its launch of Trulance. Although commercialization of the product only began in March, early signs and commentary from management are promising. Just a few highlights from the first quarter earnings call:

• Synergy's 250-person sales force has reached over 80% of top prescribers
• 1 month into launch, Trulance has exceeded expectations in terms of both adoption and penetration statistics
• 60% of adult CIC patients with commercial insurance have unrestricted coverage for Trulance
• The U.S. patent office has issued three new patients for Trulance, the earliest of which expires in September of 2031

https://www.fool.com/investing/2017/05/29/with-ardelyxs-fall-does-synergy-now-have-a-clear-p.aspx?yptr=yahoo